Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1

AIDS Research and Human Retroviruses

Volumn 16, Issue 10, 2000, Pages 935-941

  Baba, Masanori ^a,c   Miyake, Hiroshi ^b   Okamoto, Mika ^a   Iizawa, Yuji ^b   Okonogi, Kenji ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CHEMOKINE RECEPTOR CCR5;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOPATHOGENIC EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION SENSITIVITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOBLAST; VIRUS REPLICATION;

AMIDES; ANTI-HIV AGENTS; CELL CULTURE TECHNIQUES; CELL DIVISION; CELL SURVIVAL; CYTOPATHOGENIC EFFECT, VIRAL; HIV-1; HUMANS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0034234469     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050058344     Document Type: Article

References (18)

1. 1. Moore JP, Trkola A, and Dragic T: Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9:551-562.
2. 2. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Role in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
3. 3. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, and Parmentier M: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (London) 1996;382:722-725.
4. 4. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, and Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86: 367-377.
5. 5. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, and Fenyö EM: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71: 7478-7487.
6. 6. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyö EM, and Lusso P: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Med 1997;3:1259-1265.
7. 7. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, and Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nature Med 1996;2:1244-1247.
8. 8. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, and Wells TN: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599-2603.
9. 9. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schartz TW, Buser R, Wells TNC, and Proudfoot AE: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
10. 10. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, and Fujino M: A small-molecule nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-5703.
11. 11. Chackerian B, Long EM, Luciw PA, and Overbaugh J: Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol 1997;71:3932-3939.
12. 12. Kikukawa R, Koyanagi Y, Harada S, Kobayashi N, Hatanaka M, and Yamamoto N: Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic cell line Molt-4. J Virol 1986;57:1159-1162.
13. 13. Michael NL, Nelson JAE, KewalRamani VN, Chang G, O'Brien SJ, Mascola JR, Volsky B, Louder M, White GC II, Littman DR, Swanstrom R, and O'Brien TR: Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 Δ32. J Virol 1988;72: 6040-6047.
14. + T-cell lines determined by the capacity to exploit low concentrations of CCR5. J Virol 1999;73:7842-7847.
15. 15. Rucker J, Samson M, Doranz BJ, Libert F, Berson JF, Yi Y, Smith RJ, Collman RG, Broder CC, Vassart G, Doms RW, and Parmentier M: Regions in β-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 1996;87:437-446.
16. 16. Bieniasz PD, Fridell RA, Aramori I, Ferguson SSG, Caron MG, and Cullen BR: HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J 1997;16:2599-2609.
17. 17. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, Baba M, Fujii N, and Nakashima H: T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999;73:1719-1723.
18. 18. De Vreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schact S, Anné J, De Clercq E, Datema R, and Werner G: The molecular target of bicyclam, potent inhibitors of human immunodeficiency virus replication. J Virol 1996;70:689-696.